Evidence map›Paper›PMID 33575830›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2021

A sprayable Acid-Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: a new potential solution for upper respiratory tract hygiene.

Nadia Giarratana, Balan Rajan, Kannan Kamala, Michelle Mendenhall, Giorgio Reiner

Open access · hybridAbstract read
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. COVID-19 Patient Psychological Pain Factors.Frontiers in psychology · 2021
    Article
  19. Evaluation of Current Evidence on the Use of Oral Antiseptics Against SARS-CoV-2: A Narrative Review.Journal of International Society of Preventive & Community Dentistry
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Nadia GiarratanaAPR Applied Pharma Research S.A, 6828, Balerna, Switzerland. nadia.giarratana@apr.ch.ORCID http://orcid.org/0000-0001-9154-6057
Balan RajanEurofins Advinus Limited, Bengaluru, India.
Kannan KamalaEurofins Advinus Limited, Bengaluru, India.
Michelle MendenhallInstitute for Antiviral Research, Utah State University, Logan, Utah, USA.
Giorgio ReinerAPR Applied Pharma Research S.A, 6828, Balerna, Switzerland.
Applied Pharma Research (Switzerland) · CHUtah State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo eliminate the COVID-19 pandemic, the transmission of the virus SARS-CoV-2 among the population needs to be blocked and/or at least reduced. Upper respiratory tract viral loads are highest in the early stages of the disease, and high loads are associated with higher mortality rates. This study aims to evaluate the virucidal efficacy of AOS2020, a novel sprayable Acid-Oxidizing solution containing pure and stable hypochlorous acid (HClO), on human coronavirus SARS-Cov-2 in vitro, and the tolerability profile on nasal and oral mucosa suggesting to be a potential solution for upper respiratory hygiene.

methodVirucidal assays and intranasal and oral irritation tests were undertaken in accordance with relevant national and international guidance and methods.

resultsIn pre-clinical tests, the AOS2020, showed > 99.8% virucidal efficacy in < 1 min against SARS-Cov-2. The safety profile testing on both the nasal and oral mucosa indicates that AOS2020 is non-irritant.

conclusionThese initial results indicate that this product has the potential treatment to reduce viral load in the upper respiratory tract.

Indexed as

COVID-19SARS-CoV-2HumansHygieneHypochlorous AcidNoseOxidation-ReductionPandemicsHypochlorous AcidAcid-Oxidizing solution (AOS2020)Hypochlorous acid (HClO)SARS-CoV-2Upper respiratory tractViral load

Identifiers

PMID33575830
PMCPMC7877500
OpenAlexW3127430495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.